Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alcohol warning petition

This article was originally published in The Tan Sheet

Executive Summary

Pharmaceutical Formulations asks FDA to add a variance procedure to the final rule requiring alcohol warnings on all OTC analgesics allowing manufacturers, "for good cause," to obtain additional time to re-label. In the Feb. 12 citizen petition, PFI says although it "is making a good faith effort to comply" with the April 23 deadline, it still has two-thirds of its inventory, or 546 labels, to revise in less than 70 days, and does not have the manpower to "thoroughly and adequately create, review and approve such a large volume of labels within such a short time frame." The petition points out FDA's suggested use of temporary stick-on labels initially "is not feasible" because "not all of PFI's customers" will permit such labels and "many product labels simply do not have room...without obscuring the other required information." PFI concurs with the Dec. 30 petition by Perrigo also seeking an extension mechanism ("The Tan Sheet" Jan. 25, p. 19)

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts